EUVIMEDEUVIMED entdecken
Crossref

Individualizing pharmacologic and non-pharmacologic therapy for chronic kidney disease associated with diabetes

Zurong Zhang, Li Li, Ming Yang, Wei Chen, Li Xiao, Lin Sun, Rajiv Agarwal iD

Nephrology Dialysis Transplantation · 08.08.2026

DOI: 10.1093/ndt/gfag179 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 08.08.2026. Verfasst von Zurong Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, the Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, Cha…. Die Arbeit nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic kidney disease (DKD) now has more proven kidney-protective therapies than at any previous time: renin–angiotensin system inhibitors (RASi), sodium–glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and the nonsteroidal mineralocorticoid receptor antagonist (nsMRA) finerenone. However, no head-to-head randomized controlled trial (RCT) has compared these classes, no Phase 3 trial has confirmed that specific multi-class combinations improve hard outcomes beyond well-selected monotherapy; and long-term safety of sustained combination therapy has not been fully characterized. This review synthesizes contemporary evidence for kidney-protective therapy in adults with DKD, emphasizing that non-pharmacologic measures—blood pressure control, individualized glycemic targets, sodium and protein moderation, structured exercise, weight management, and smoking cessation—should be intensified concurrently with drug therapy. We propose an individualization framework that selects agents whose mechanisms address more than one of the patient’s clinical problems simultaneously and avoids those whose adverse effects conflict with active comorbidities. Combination therapy is biologically rational and supported by additive albuminuria reduction (CONFIDENCE) and lifetime modeling, but hard-outcome confirmation is absent. Until such trials are available, the most defensible framework is an individualized, monitoring-based strategy that adapts through addition, hold, or deprescribing based on clinical evolution.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistsSGLT2 inhibitorsdiabetic kidney diseasefinerenoneindividualized therapy

Autor:innen und Institutionen

  • Department of Nephrology, the Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, Hunan, China.
  • Division of Nephrology, Richard L. Roudebush VA Medical Center, and Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID-Profile: Rajiv Agarwal

Zitieren

APA

Zhang, Z., Li, L., Yang, M., Chen, W., Xiao, L., Sun, L., & Agarwal, R. (2026). Individualizing pharmacologic and non-pharmacologic therapy for chronic kidney disease associated with diabetes. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag179

Vancouver

Zhang Z, Li L, Yang M, Chen W, Xiao L, Sun L, et al. Individualizing pharmacologic and non-pharmacologic therapy for chronic kidney disease associated with diabetes. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag179

BibTeX
@article{Zhang2026,
  author = {Zhang, Zurong and Li, Li and Yang, Ming and Chen, Wei and Xiao, Li and Sun, Lin and Agarwal, Rajiv},
  title = {Individualizing pharmacologic and non-pharmacologic therapy for chronic kidney disease associated with diabetes},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag179}
}
Kostenlos starten →